Contact 01 58 86 39 60   |   contact@institut-hypercube.org
Institut HyperCube
  • ABOUT US
  • PROJECTS
  • PARTNERS
  • PUBLICATIONS
  • FEATURED NEWS
    • PRESS
    • EVENTS
  • SUPPORT US
    • HOW TO SUPPORT
    • MAKE A DONATION
  • CONTACT
  • Français

Lung Cancer

Logo_Gustave_Roussy_2

 

LUNG CANCER

Survival of lung cancer treated with resection

Context

Lung cancer is the leading cause of cancer deaths in the world. The prognosis of non–small cell lung carcinoma (NSCLC) largely depends on tumor stage; indeed, the overall low survival rate (about 15% at 5 years) is primarily due to the high frequency of late diagnosis, when the tumor has become unresectable. Early-stage NSCLC patients (stage I–II) have a significantly better prognosis (30%–60% survival at 5 years). One important issue in stage I NSCLC is that current diagnostic tools do not allow precise prognostic evaluation. In turn, this limits the power of clinical trials aimed at ameliorating prognosis through multimodality therapy. A case in point is represented by adjuvant chemotherapy, on which conflicting results in stage IB have been reported. Consequently, there is presently no indication for adjuvant treatment in stage I NSCLC. Evidently enough, the availability of accurate prognostic markers might change this picture by allowing the selection, for clinical trials, of only those patients with a high risk of relapse. Thus, there is need for reliable prognostic indicators, both for diagnostic and prognostic purposes and for the design of clinical trials.

Purpose of the study

Improve the prognosis of patients detected with early-stage lung cancer

Results to date

diams_3  Discovery of a new gene expression signature that robustly predicts the outcome of patients diagnosed with early-stage lung cancer

diams_3  Presentation of a poster in the 2014 Esmo Congress : Best Poster Award

diams_3  Request for grant of an European patent

Other partners on this project
Bearingpoint_logo
Support us on this research project by making a donation:
MAKE A DONATION
visuel_tablette_autisme

Autism

13 May 2016

Porphyria

13 May 2016

blood2

Acute Myeloid Leukemia

14 May 2016

6405383

Congenital Malformations

14 May 2016

Institut HyperCube
  • ABOUT US
  • CONTACT
  • LEGAL
Copyright ©2015 Institut HyperCube. Tous droits réservés